Clinical Trial Finder

Inclusion Criteria:

• - Age: ≥ 65 years; - Living in Nanshan, Shenzhen for at least 5 years; - Chinese.

Exclusion Criteria:

• - Had a history of hospital-confirmed diabetes, failure(s) of heart, liver, or kidney, cancer, CVD events; - On special diet due to a disease or weight control; - Mental and physical disability; - Likely to move to other city within 5 years; - Did not want to attend any one item of the survey or sample collection.

Objective: The Nanshan Elderly Cohort Study (NECS) aims to investigate the nutritional, as well as other environmental and genetic factors of chronic diseases, such as hypertension, type 2 diabetes mellitus, cardiovascular diseases, stroke, obesity, metabolic syndrome, chronic kidney disease, cancer and sarcopenia. Study design: NECS is a community-based prospective cohort study. Participants: Healthy residents who had lived in Nanshan， Shenzhen (South China) for >5 years, aged ≥ 65 years are eligible. Participants would be excluded if they are confirmed to have serious chronic diseases, such as cardiovascular disease, liver or renal failure, or cancer. About 10000-20000 apparently healthy residents will be recruited between 2018 and 2019. Visits and Data Collection: Participants will be followed up approximately every 3 years by invited to the Community Healthcare Service Centre. At each survey, face-to-face interviews, anthropometric measurements, ultrasonography examinations, electrocardiogram test and specimen collection will be conducted. Key variables: 1. Face-to-face interviews: Structured questionnaires will be used to collect the participants' socio-demographic characteristics (e.g., age, sex and household income, education level), lifestyles (smoking, passive smoking, alcohol and tea drinking), habitual dietary intake (a 62-item quantitative food frequency questionnaire), physical activity, history of chronic diseases, use of supplements and medications, family history, psychological health (Self-Rating Anxiety Scale, SAS), social support and participation, cognitive function (Mini-Mental State Examinations, MMSE); 2. Physical examinations: Anthropometric measurements (weight, height, waist, hip and neck circumference, etc.), blood pressure tests, handgrip strength, and usual gait speed. 3. Ultrasonography examinations: Ultrasonography examination of the carotid artery and upper abdominal organs (e.g., liver and kidney) will be performed to determine carotid artery intima-media thickness and plaque, fatty liver. 4. Electrocardiogram test: Electrocardiogram test is to obtain information about the structure and function of the heart. 5. Specimen collections: Overnight fasting blood sample will be collected and separated into serum, plasma, red blood cell and leukocyte within two hours. Early morning first-void urine sample and faeces samples will be collected. All specimens will separated and stored at -80°C till tests. 6. Laboratory tests: 1. Metabolic syndrome-related indices: Fasting serum lipid profile (e.g., cholesterol, triglycerides, high-density lipoprotein cholesterol and low-density lipoprotein cholesterol), diabetes-related indices (e.g., glucose, glycated hemoglobin, fructosamine and insulin), uric acid and creatinine; 2. Nutritional indices: Serum concentrations of carotenoids, erythrocyte fatty acids, serum minerals, folate, betaine, choline, TMAO, and vitamin D, etc. 3. Inflammatory markers (e.g., hsCRP, RBP4，IL-6, TNF-a) 4. Sexual hormones (e.g., testosterone, SHBG) 5. Genetic markers. 6. Urinary tests: Flavonoids and flavones, minerals, creatinine and renal function related markers. 7. Fecal test: Gut microbiota and related metabolites. 7. Morbidity and mortality: Relevant data will be also retrieved via local multiple Health information systems. 8. Others: Many other laboratory tests or instrument tests will be developed depended on needs and resources in future. Statistical analysis: Cox proportional hazards models or logistic regression models will be used to estimate the risk of exposures on categorical outcomes. Path analysis also will be used to assess the potential mediating effects in the causal pathway between exposures and outcomes.